Xin Lang Cai Jing·2025-09-25 01:54Core Viewpoint - Rongchang Biopharmaceuticals has shown a significant increase in stock price, reflecting positive market sentiment and investor interest in its innovative biopharmaceutical products [1] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is located in the Yantai Free Trade Zone, Shandong, China [1] - The company focuses on the development and commercialization of innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The main revenue sources are from product sales (99.46%), material sales (0.38%), and leasing services (0.16%) [1] Financial Performance - As of the report date, Rongchang Biopharmaceuticals' stock price is 110.17 CNY per share, with a market capitalization of 62.093 billion CNY and a trading volume of 2.19 billion CNY [1] Fund Holdings - Jiahe Fund has a significant holding in Rongchang Biopharmaceuticals through its Jiahe Jinpeng Tianli Mixed A fund, which held 200,000 shares, accounting for 1.69% of the fund's net value [2] - The fund has generated a floating profit of approximately 1.054 million CNY from this investment [2] Fund Manager Information - The fund managers of Jiahe Jinpeng Tianli Mixed A are Yu Qiming and Ji Huijuan, with respective tenures of 13 years and 10 years [3] - The fund has a total asset scale of 156.9 billion CNY and 206.49 billion CNY, with historical best returns of 48.33% and 38.43% respectively [3]